Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2012 December;60(6) > Minerva Cardioangiologica 2012 December;60(6):637-41

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints

 

CASE REPORTS   

Minerva Cardioangiologica 2012 December;60(6):637-41

Copyright © 2012 EDIZIONI MINERVA MEDICA

language: English

Ventricular tachycardia in “end stage” hypertrophic cardiomyopathy: a role of dronedarone

Nanda S., Levin V., Martinez M. W.

Division of Cardiovascular Medicine, Lehigh Valley Health Network, Allentown, PA, USA


PDF


Hypertrophic cardiomyopathy (HCM) occurs in 1 in every 500 individuals. It represents the most common cause of sudden cardiac death in those under the age of twenty-five. 3-5% patients with HCM go on to develop the dilated, hypokinetic end stage (ES) HCM with systolic failure. They have a higher incidence of heart failure, sudden deaths and defibrillator shocks. To the best of our knowledge this is first report of successful use of dronedarone for suppression of VT associated with ES HCM.

top of page